Format

Send to

Choose Destination
Pharmacotherapy. 2013 Apr;33(4):363-8. doi: 10.1002/phar.1213. Epub 2013 Feb 28.

Asthma drugs and the risk of congenital anomalies.

Author information

1
Department of Epidemiology, Boston University School of Public Health, Boston, MA, USA.

Abstract

STUDY OBJECTIVE:

To estimate the prevalence of congenital anomalies between the offspring of women exposed and unexposed to asthma drugs during early pregnancy.

DESIGN:

Matched cohort study.

DATABASE:

The United Kingdom's General Practice Research Database.

PATIENTS:

Women exposed to asthma drugs during early pregnancy and a sample of matched unexposed pregnant women.

MEASUREMENTS AND MAIN RESULTS:

The prevalence of any anomaly among unexposed and exposed women was 27.8 (95% confidence interval [CI] 25.4-30.6)/1000 pregnancies and 31.3 (95% CI 27.7-35.5)/1000 pregnancies, respectively (relative risk [RR] 1.1 95% CI 1.0-1.3).

CONCLUSION:

Our findings suggest that asthma drugs, overall, do not increase the risk of congenital anomalies in the offspring when taken during the first trimester of pregnancy.

PMID:
23450814
DOI:
10.1002/phar.1213
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center